The outcome of antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: A single-center study

dc.contributor.buuauthorÖzkocaman, Vildan
dc.contributor.buuauthorÖzkalemkaş, Fahir
dc.contributor.buuauthorSeyhan, Serdar
dc.contributor.buuauthorEner, Beyza
dc.contributor.buuauthorUrsavaş, Ahmet
dc.contributor.buuauthorErsal, Tuba
dc.contributor.buuauthorKazak, Esra
dc.contributor.buuauthorDemirdöğen, Ezgi
dc.contributor.buuauthorMıstık, Reşit
dc.contributor.buuauthorAkalın, Halis
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Mikrobiyoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları ve Tüberküloz Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-4803-8206tr_TR
dc.contributor.orcid0000-0002-7400-9089tr_TR
dc.contributor.researcheridAAI-3169-2021tr_TR
dc.contributor.researcheridAAG-8459-2021tr_TR
dc.contributor.researcheridAAH-1854-2021tr_TR
dc.contributor.researcheridAAJ-4354-2021tr_TR
dc.contributor.researcheridAAU-8952-2020tr_TR
dc.contributor.researcheridAAG-8523-2021tr_TR
dc.contributor.researcheridAAH-9812-2021tr_TR
dc.contributor.researcheridAAG-8495-2021tr_TR
dc.contributor.scopusid6603145040tr_TR
dc.contributor.scopusid6601912387tr_TR
dc.contributor.scopusid56154853700tr_TR
dc.contributor.scopusid15053025300tr_TR
dc.contributor.scopusid8329319900tr_TR
dc.contributor.scopusid56061031700tr_TR
dc.contributor.scopusid24921238200tr_TR
dc.contributor.scopusid14062849300tr_TR
dc.contributor.scopusid6602564624tr_TR
dc.contributor.scopusid57207553671tr_TR
dc.date.accessioned2023-11-20T06:35:49Z
dc.date.available2023-11-20T06:35:49Z
dc.date.issued2018-07-26
dc.description.abstractObjective: Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality among neutropenic patients undergoing chemotherapy for acute myeloid leukemia (AML) and stem cell transplantation. The aim of this study was to evaluate the real-life impact of posaconazole prophylaxis. Materials and Methods: Eighty-four adult patients were included with AML under remission induction chemotherapy and posaconazole prophylaxis. The 34 patients in the control group did not receive primary antifungal prophylaxis. The period between June 2006 and January 2009, when antifungal prophylaxis was not administered (control group), was retrospectively compared to the period between December 2010 and May 2012 when primary oral posaconazole prophylaxis was administered in similar conditions (posaconazole group) according to the use of antifungal agents for treatment, breakthrough infections, galactomannan performance, and the necessity for performing bronchoalveolar lavage (BAL) procedures. Results: The two groups were compared according to the use of antifungal agents; progression to a different antifungal agent was found in 34/34 patients (100%) in the control group and in 9/84 patients (11%) in the posaconazole group (p<0.001). There were four breakthrough IFIs (4/84, 4.8%) in the posaconazole group and 34 IFIs in the control group (p<0.001). In addition, 15/34 patients (44%) in the control group required BAL compared to 11/84 patients (13%) in the posaconazole group (p<0.001). Posaconazole treatment was discontinued within 7-14 days in 7/84 patients (8.3%) due to poor oral compliance related to mucositis after chemotherapy. Conclusion: Posaconazole appears to be effective and well-tolerated protection against IFIs for AML patients.en_US
dc.description.abstractAmaç: İnvaziv fungal enfeksiyonlar (İFE) akut myeloid lösemili (AML) ve kök hücre nakli yapılan hastalarda önemli bir mortalite ve morbidite nedenidir. Bu çalışmanın amacı posakonazol profilaksisinin gerçek yaşamdaki etkisini değerlendirmektir. Gereç ve Yöntemler: AML ve remisyon indüksiyon kemoterapisi alan ve posakonazol profilaksisi uygulanan 84 erişkin hasta çalışmaya dahil edildi. Kontrol grubunda primer antifungal profilaksi almayan 34 hasta dahil edildi. Haziran 2006 ile Ocak 2009 tarihleri arası primer oral posakonazol profilaksisi almayan (kontrol grubu) ile Aralık 2010 ile Mayıs 2012 arası primer oral posakonazol profilaksisi (posakonazol grubu) uygulanan hastaları geriye dönük olarak; tedavi için antifungal ajan kullanımı, tedavi altında (breakthrough) enfeksiyonlar, galaktomannan performansı ve bronko-alveolar lavaj (BAL) gerekliliği gibi benzer durumlar için karşılaştırdık. Bulgular: İki grup antifungal ajan kullanımına göre karşılaştırıldığında farklı antifungal ajana geçiş kontrol grubunda 34/34 (%100) idi ve posakonazol grubunda bu oran 9/84 (%11) bulundu (p<0,001). Posakonazol grubunda 4 tedavi altında (breakthrough) IFE (4/84, %4,8) ve kontrol grubunda ise 34 İFE vardı (p<0,001). İlaveten kontrol grubunda BAL gereken hasta 15/34 (%44) iken, posakonazol grubunda BAL gerekliliği 11/84 (%13) bulundu (p<0,001). Posakonazol tedavisi hastaların 7/84’ünde (%8,3) kemoterapi sonrası mukozite bağlı oral alım bozukluğu nedeniyle 7-14 gün içinde kesilmişti. Sonuç: Posakonazol AML’li hastaların invaziv fungal enfeksiyonlarına karşı korumada etkili ve iyi tolere ediliyor görünmektedir.tr_TR
dc.identifier.citationÖzkocaman, V. vd. (2018). ''The outcome of antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: A single-center study''. Turkish Journal of Hematology, 35(4), 277-282.tr_TR
dc.identifier.endpage282tr_TR
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue4tr_TR
dc.identifier.pubmed30047484tr_TR
dc.identifier.scopus2-s2.0-85056360194tr_TR
dc.identifier.startpage277tr_TR
dc.identifier.urihttps://doi.org/10.4274/tjh.2017.0430
dc.identifier.urihttps://jag.journalagent.com/tjh/pdfs/TJH_35_4_277_282.pdf
dc.identifier.urihttp://hdl.handle.net/11452/34941
dc.identifier.volume35tr_TR
dc.identifier.wos000456836500006
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.trdizinTrDizintr_TR
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherGalenos Yayıncılıktr_TR
dc.relation.journalTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcute myeloid leukemiaen_US
dc.subjectInvasive fungal infectionsen_US
dc.subjectAntifungal prophylaxisen_US
dc.subjectPosaconazoleen_US
dc.subjectBronchoalveolar lavage fluiden_US
dc.subjectInvasive fungal-infectionsen_US
dc.subjectAcute myelogenous leukemiaen_US
dc.subjectAspergillosisen_US
dc.subjectGalactomannanen_US
dc.subjectFluconazoleen_US
dc.subjectGuidelinesen_US
dc.subjectItraconazoleen_US
dc.subjectChemotherapyen_US
dc.subjectExperienceen_US
dc.subjectAkut myeloid lösemien_US
dc.subjectİnvaziv fungal enfeksiyonlaren_US
dc.subjectAntifungal profilaksien_US
dc.subjectPosaconazolen_US
dc.subjectHemotologyen_US
dc.subject.emtreeAmphotericin B.en_US
dc.subject.emtreeAmphotericin B lipid complexen_US
dc.subject.emtreeFluconazoleen_US
dc.subject.emtreeGalactomannanen_US
dc.subject.emtreeItraconazoleen_US
dc.subject.emtreePosaconazoleen_US
dc.subject.emtreeVoriconazoleen_US
dc.subject.emtreeAntifungal agenten_US
dc.subject.emtreePosaconazoleen_US
dc.subject.emtreeTriazole derivativeen_US
dc.subject.emtreeAcute myeloid leukemiaen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAntifungal activityen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeAspergillusen_US
dc.subject.emtreeCancer regressionen_US
dc.subject.emtreeComputer assisted tomographyen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDrug substitutionen_US
dc.subject.emtreeDrug withdrawalen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInduction chemotherapyen_US
dc.subject.emtreeInfection preventionen_US
dc.subject.emtreeInvasive aspergillosisen_US
dc.subject.emtreeLung lavageen_US
dc.subject.emtreeLung scintiscanningen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMedical decision makingen_US
dc.subject.emtreeMedication complianceen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeMucosa inflammationen_US
dc.subject.emtreeNeutropeniaen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeSalvage therapyen_US
dc.subject.emtreeSuspensionen_US
dc.subject.emtreeSystemic mycosisen_US
dc.subject.emtreeAcute myeloid leukemiaen_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeOral drug administrationen_US
dc.subject.emtreeYoung adulten_US
dc.subject.meshAdministration, oralen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntifungal agentsen_US
dc.subject.meshHumansen_US
dc.subject.meshLeukemia, myeloid, acuteen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshTriazolesen_US
dc.subject.meshYoung adulten_US
dc.subject.scopusAntifungal Agents; Posaconazole; Micafunginen_US
dc.subject.wosHematologyen_US
dc.titleThe outcome of antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: A single-center studyen_US
dc.title.alternativeAkut myeloid lösemili hastalarda posakonazol ile antifungal profilaksi sonuçları: Tek merkez çalışmasıtr_TR
dc.typeArticle
dc.wos.quartileQ4en_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Özkocaman_vd_2018.pdf
Size:
214.2 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: